Presence of phosphodiester backbone, but not nucleobases, in the guide’s 3′ terminal region is necessary for RISC loading and target cleavage in vitro and in vivo
Nucleic Acids Research · 2026
DOI: 10.1093/nar/gkaf1438 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2026. Verfasst von Daniel O'Reilly und 16 weiteren Autor:innen. Beteiligte Einrichtung: RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA 01605, United States. Hauptthemen laut MEDLINE: RNA, Small Interfering, RNA-Induced Silencing Complex. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, NIGMS NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Short interfering RNAs (siRNAs) represent a novel class of therapeutic modalities, where, in the context of complex chemical modification patterns, a single administration can support sustained gene silencing. Various siRNA architectures demonstrate robust activity; however, a guide strand length of 19–21 nucleotides is generally believed to be required for effective gene silencing. Here, we show that up to five terminal positions of the guide strand can be efficiently substituted with non-nucleobase-containing analogs without a measurable loss of activity in vitro or in vivo. While nucleobases are not essential at these positions, the presence of a phosphodiester backbone is critical. Both the distance between phosphate groups and the lipophilicity of the phosphodiester-linking analogs significantly influence silencing activity. Longer carbon-based chains reduce activity, whereas ethylene glycol-based chains preserve activity, highlighting the importance of backbone architecture in RISC engagement. These findings demonstrate that non-nucleobase structures can support productive RISC interactions, offering new opportunities in the chemical engineering of therapeutic siRNAs and other classes of small-RNA drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA 01605, United States.
- Sealy Institute for Drug Discovery, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, United States.
ORCID-Profile: Vignesh Hariharan, Hassan H Fakih, Julia F Alterman, Dimas Echeverria, Jonathan K Watts, Anastasia Khvorova
Förderung
- NIH HHS
- NIGMS NIH HHS
- NINDS NIH HHS
- Hereditary Disease Foundation
- National Institutes of Health
Zitieren
APA
O'Reilly, D., Furgal, R. C., Ross, V. M., Luu, E., Gross, K. Y., Hariharan, V., Summers, A., Cooper, D., Allen, S., Dahlke, C., Rachid, M. O., Chan, I. L., Fakih, H. H., Alterman, J. F., Echeverria, D., Watts, J. K., & Khvorova, A. (2026). Presence of phosphodiester backbone, but not nucleobases, in the guide’s 3′ terminal region is necessary for RISC loading and target cleavage in vitro and in vivo. Nucleic Acids Research. https://doi.org/10.1093/nar/gkaf1438
Vancouver
O'Reilly D, Furgal RC, Ross VM, Luu E, Gross KY, Hariharan V, et al. Presence of phosphodiester backbone, but not nucleobases, in the guide’s 3′ terminal region is necessary for RISC loading and target cleavage in vitro and in vivo. Nucleic Acids Research. 2026. doi:10.1093/nar/gkaf1438
BibTeX
@article{OReilly2026,
author = {O'Reilly, Daniel and Furgal, Raymond C and Ross, Vella M and Luu, Eric and Gross, Katherine Y and Hariharan, Vignesh and Summers, Ashley and Cooper, David and Allen, Sarah and Dahlke, Christopher and Rachid, Mohamad Omar and Chan, Io Long and Fakih, Hassan H and Alterman, Julia F and Echeverria, Dimas and Watts, Jonathan K and Khvorova, Anastasia},
title = {Presence of phosphodiester backbone, but not nucleobases, in the guide’s 3′ terminal region is necessary for RISC loading and target cleavage in vitro and in vivo},
journal = {Nucleic Acids Research},
year = {2026},
doi = {10.1093/nar/gkaf1438}
}
EUVIMED